Results 281 to 290 of about 105,039 (329)

Low Dose of IL‐2 Application for Graft‐Versus‐Host Disease Prophylaxis Following Haploidentical Stem Cell Transplantation

open access: yesMedComm, Volume 7, Issue 2, February 2026.
Early low‐dose IL‐2 administration after haploidentical HSCT promotes the reconstitution of NK cells and regulatory T cells (Tregs), enhances their activation (CD122+, DNAM‐1+, NKG2D+, CD62L+), and increases plasma cytokines (IFN‐γ, TNF‐α, IL‐10, IL‐2).
Zheng‐Li Xu   +13 more
wiley   +1 more source

Role of Acid‐Sensing Ion Channels 1a in the Regulation of Obesity and the Gut Microbiota

open access: yesObesity, Volume 34, Issue 2, Page 372-381, February 2026.
ABSTRACT Objective Acid‐sensing ion channels are proton‐activated ion channels predominantly found in the nervous system. They are well known to affect metabolic and neurological health, yet their role in obesity and gut physiology remains unclear. This study investigates how systemic deletion of Asic1a influences obesity, metabolic, and gut‐based ...
Jane Shearer   +7 more
wiley   +1 more source

Effect of the national integrated demonstration area for the prevention and control of noncommunicable diseases programme on behavioural risk factors in China: a synthetic difference-in-differences study

open access: gold
Wenlan Dong   +13 more
openalex   +1 more source

Real‐world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 895-905, February 2026.
Abstract Aim A retrospective observational cohort study, in the Netherlands, evaluated clinical outcomes with oral semaglutide. Methods Glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) naïve type 2 diabetes (T2D) patients who initiated oral semaglutide between 1 January 2020 and 31 December 2022 were identified from the PHARMO Data Network.
Abigail Postema   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy